Thermo Fisher Scientific Eyes Acquisition of QIAGEN in Potential Blockbuster Deal

(Bloomberg) -- 11Month13News on [Date]: According to insiders, Thermo Fisher Scientific, a giant in the diagnostics and life sciences industry, stated that it is considering acquiring molecular diagnostics company QIAGEN (Qiagen), which could become one of the largest mergers and acquisitions in its history.

The aforementioned individual stated that Thermo Fisher Scientific has approached QIAGEN regarding a potential merger and acquisition deal. The source, who requested anonymity, declined to provide further details, citing the confidential nature of the information. QIAGEN is listed on the NASDAQ in New York and the Frankfurt Stock Exchange, with a market capitalization of approximately73100 million U.S. dollars.

The aforementioned individuals stated that it remains uncertain whether these discussions will lead to a transaction, and other potential bidders for QIAGEN may also emerge.

Introduction to Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving science. The company has annual sales exceeding $20 billion and employs approximately 65,000 people worldwide.

Our mission is to partner with our customers to make the world healthier, cleaner, and safer. We help customers accelerate research in the life sciences, address complex challenges in analytical science, advance medical diagnostics, expedite drug development, and enhance laboratory productivity.

Leveraging our premier brands—Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services—we lead the way in delivering comprehensive solutions that integrate innovative technologies, streamlined procurement, and end-to-end services.

QIAGEN Profile

QIAGEN, founded in 1984 and headquartered in Hilden, Germany, is a multinational biotechnology company and a global leader in sample and assay technologies. QIAGEN is listed on the NASDAQ in New York and the Frankfurt Stock Exchange, and is a constituent of the NASDAQ-100 Index.

QIAGEN has branches in nearly 40 cities across more than 20 countries worldwide, with over 60 offices and more than 3,700 employees. QIAGEN’s molecular testing technologies are applied in four major areas: clinical diagnostics, non-clinical applications, scientific research, and biopharmaceuticals. The company holds 2,500 patents and licenses, offers up to 500 instruments and solutions, and serves more than 500,000 customers.